JP2020522567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522567A5 JP2020522567A5 JP2020516787A JP2020516787A JP2020522567A5 JP 2020522567 A5 JP2020522567 A5 JP 2020522567A5 JP 2020516787 A JP2020516787 A JP 2020516787A JP 2020516787 A JP2020516787 A JP 2020516787A JP 2020522567 A5 JP2020522567 A5 JP 2020522567A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hydrogen
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 206010023330 Keloid scar Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000008602 contraction Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 210000001117 keloid Anatomy 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010060932 Postoperative adhesion Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 Cc(cc1C(c(c2c3)ccc3S(N(*)*)=O)=*)c(*)cc1C2=NO* Chemical compound Cc(cc1C(c(c2c3)ccc3S(N(*)*)=O)=*)c(*)cc1C2=NO* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514541P | 2017-06-02 | 2017-06-02 | |
| US62/514,541 | 2017-06-02 | ||
| PCT/US2018/035646 WO2018223023A1 (en) | 2017-06-02 | 2018-06-01 | Methods for treatment of fibrotic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522567A JP2020522567A (ja) | 2020-07-30 |
| JP2020522567A5 true JP2020522567A5 (https=) | 2021-07-26 |
| JP7159302B2 JP7159302B2 (ja) | 2022-10-24 |
Family
ID=64456126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516787A Active JP7159302B2 (ja) | 2017-06-02 | 2018-06-01 | 線維性疾患の治療のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11298346B2 (https=) |
| EP (2) | EP4656191A1 (https=) |
| JP (1) | JP7159302B2 (https=) |
| CA (1) | CA3065318A1 (https=) |
| ES (1) | ES3055488T3 (https=) |
| WO (1) | WO2018223023A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
| CN118105343A (zh) * | 2018-06-01 | 2024-05-31 | 伊特里恩治疗有限公司 | 特加维因和相关化合物的制剂 |
| EP4081209A4 (en) * | 2019-12-24 | 2024-04-24 | The Regents of the University of California | Compositions and methods for treating cancer and improving epithelial homeostasis |
| WO2021207380A1 (en) * | 2020-04-08 | 2021-10-14 | The Trustees Of Indiana University | Therapeutic strategies to manage facial contractures post injury |
| US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
| US11964054B2 (en) | 2020-11-24 | 2024-04-23 | Iterion Therapeutics, Inc. | Formulations of tegavivint |
| US11571388B2 (en) | 2020-11-24 | 2023-02-07 | Iterion Therapeutics, Inc. | Lyophilized formulations of tegavivint |
| CN119215047A (zh) * | 2024-10-11 | 2024-12-31 | 浙江大学 | 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2152258B1 (en) | 2007-05-10 | 2016-05-04 | Avalon Pharmaceuticals | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
| WO2010059142A1 (en) | 2008-11-21 | 2010-05-27 | Avalon Pharmaceuticals | Anthraquinone dioximes and uses thereof |
| CA2782472C (en) * | 2009-12-15 | 2019-04-16 | The Hospital For Sick Children | Method of treating scars and beta-catenin-mediated disorders |
| AU2012332111B2 (en) | 2011-11-06 | 2016-11-17 | Beta Cat Pharmaceuticals, Llc | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia |
| WO2013071232A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| EP2968321A4 (en) * | 2013-03-14 | 2016-11-09 | Curegenix Inc | COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES |
| EP3328819B1 (en) | 2015-07-28 | 2020-04-01 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compounds prodrugs and their uses |
| KR102651136B1 (ko) * | 2016-04-12 | 2024-03-25 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 및 그 제조 방법 |
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| CN118105343A (zh) * | 2018-06-01 | 2024-05-31 | 伊特里恩治疗有限公司 | 特加维因和相关化合物的制剂 |
| US11571388B2 (en) * | 2020-11-24 | 2023-02-07 | Iterion Therapeutics, Inc. | Lyophilized formulations of tegavivint |
-
2018
- 2018-06-01 EP EP25199000.8A patent/EP4656191A1/en active Pending
- 2018-06-01 ES ES18809912T patent/ES3055488T3/es active Active
- 2018-06-01 US US15/995,917 patent/US11298346B2/en active Active
- 2018-06-01 JP JP2020516787A patent/JP7159302B2/ja active Active
- 2018-06-01 EP EP18809912.1A patent/EP3630101B1/en active Active
- 2018-06-01 CA CA3065318A patent/CA3065318A1/en active Pending
- 2018-06-01 WO PCT/US2018/035646 patent/WO2018223023A1/en not_active Ceased
-
2022
- 2022-03-29 US US17/707,486 patent/US20230012615A1/en active Pending
-
2025
- 2025-12-09 US US19/413,648 patent/US20260102382A1/en active Pending